chufangao/CTO huggingface dataset:
Clinical trial NCT03316170: Consultation, Advice, and Tailored Support (CATS) for Cancer Survivors
Official title: Consultation, Advice, and Tailored Support (CATS) for Cancer Survivors
Sponsor: University of Kentucky (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 49.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-06
Primary completion date: 2020-03-31
Completion date: 2020-03-31
Baseline population: Each participant is 1 unit in the analysis
Plan to share individual participant data: NO
Clinical trial NCT05107739: A Study of DeTIL-0255 in Adults With Advanced Malignancies
Official title: A Phase 1 Safety and Tolerability Study of DeTIL-0255 in Adults With Advanced Malignancies
Sponsor: Nurix Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor Decision
Enrollment: 5.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-12-22
Primary completion date: 2023-05-09
Completion date: 2023-05-09
Plan to share individual participant data: NO
Clinical trial NCT05433298: Mesenchymal Stromal Cells for the Treatment of Patients With COVID-19.
Official title: Multicenter Phase I/IIa Study of Mesenchymal Stromal Cells for the Treatment of Patients With SARS-CoV-2 Pneumonia.
Sponsor: Pontifícia Universidade Católica do Paraná (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: No patient could be included because there was a decrease in the number of patients with complications due to COVID-19. Also, a Brazilian government agency granted this clinical trial, and the project execution period ended in March 2023.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-01
Primary completion date: 2022-11-26
Completion date: 2023-03-31
Plan to share individual participant data: NO
Clinical trial NCT04329611: ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease
Official title: A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease.
Sponsor: University of Calgary (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Enrolment was suspended on 22may2020, after Mehra et al (Lancet 2020) then stopped due to lack of Covid19 cases.
Enrollment: 148.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-13
Primary completion date: 2020-07-20
Completion date: 2020-07-20
Plan to share individual participant data: YES
IPD time frame: 24 months after study close out.
IPD access criteria: pending.
Clinical trial NCT02426658: Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3
Official title: A Pilot Study Evaluating Pemetrexed in ECOG Performance Status 3 Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 16.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-05-31
Primary completion date: 2018-04-19
Completion date: 2022-10-07
Plan to share individual participant data: NO
Clinical trial NCT04727229: Stellate Ganglion Block for Major Depressive Disorder.
Official title: Stellate Ganglion Block for Major Depressive Disorder: A Randomized Controlled Pilot Trial
Sponsor: Unity Health Toronto (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-23
Primary completion date: 2022-02-10
Completion date: 2022-03-10
Plan to share individual participant data: NO
IPD sharing description: No individual participant data has been planned to be shared with other researchers at this point since this is a feasibility study with only 10 participants.
Clinical trial NCT04249037: Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV
Official title: Prospective Pilot Study of the Efficacy, Safety and Tolerability of Bictegravir-Based HIV ART Same-Day Treatment Evaluations (B-HASTE)
Acronym: B-HASTE
Sponsor: University of Colorado, Denver (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Insufficient enrollment
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-15
Primary completion date: 2023-07-01
Completion date: 2023-07-01
Plan to share individual participant data: NO
Clinical trial NCT04760314: A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis
Official title: A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Japanese Patients With Moderate-to-Severe Atopic Dermatitis
Acronym: ADhere-J
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 286.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-03-10
Primary completion date: 2022-07-31
Completion date: 2023-02-01
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT04210310: High Dose Oxytocin Nasal Spray for Treatment of Tinnitus
Official title: A Pilot, Proof of Concept, Placebo-controlled, Parallel Study of the Effects of High Dose Intranasal Oxytocin for the Treatment of Tinnitus
Sponsor: NYU Langone Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: PI departure from the institution.
Enrollment: 33.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-15
Primary completion date: 2022-05-10
Completion date: 2022-05-10
Limitations and caveats: Study was prematurely terminated due to PI/Study Team departure from institution. No outcome measure data collected or analyzed. All participants lost to follow-up.
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
IPD time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
IPD access criteria: The investigator who proposed to use the data.Upon reasonable request. Requests should be directed to Lawrence.newman@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
Clinical trial NCT02677701: Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)
Official title: TEACH Trial: Testing the Effect of Adding CHronic Azithromycin to Inhaled Tobramycin. A Randomized, Placebo-controlled, Double-blinded Trial of Azithromycin 500mg Thrice Weekly in Combination With Inhaled Tobramycin
Acronym: TEACH
Sponsor: Seattle Children's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 119.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-10-21
Primary completion date: 2020-02-13
Completion date: 2020-02-13
Baseline population: Modified intent-to-treat population (m-ITT) defined as all randomized participants who received at least one dose of study drug.
Clinical trial NCT05431582: Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
Official title: Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: No participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-12-14
Primary completion date: 2022-12-14
Completion date: 2022-12-14
Clinical trial NCT02269917: Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants
Official title: A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor (bPI) Combined With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) in Virologically-suppressed, Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects
Sponsor: Janssen R&D Ireland (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1149.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-03-31
Primary completion date: 2017-02-28
Completion date: 2020-10-31
Baseline population: Intent-to-treat (ITT) analysis set included all the participants who were randomized and received at least 1 dose of study treatment.
Limitations and caveats: The limitation of the study was the open-label design.
Clinical trial NCT02811133: Inositol for Comorbid Anxiety in Children and Adolescents With Bipolar Disorder
Official title: Inositol for Comorbid Anxiety in Children and Adolescents With Bipolar Disorder
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Funding terminated
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-08-31
Primary completion date: 2023-10-04
Completion date: 2023-10-04
Plan to share individual participant data: YES
IPD sharing description: Upon request from other researchers, we will make available de-identified subject data, as appropriate.
IPD time frame: Data will be shared, as deemed appropriate, starting 6 months after completion of the study for a period of 5 years.
IPD access criteria: Biomedical researcher involved in research activity in a related field and from an established research institution.
Clinical trial NCT02974257: Thiamine vs. Placebo to Increase Oxygen Consumption After Cardiac Arrest
Official title: Randomized, Double-blind, Placebo-controlled Trial of the Effect of Thiamine on Oxygen Consumption After In-hospital Cardiac Arrest.
Sponsor: Beth Israel Deaconess Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study stopped early after consultation with DSMB
Enrollment: 36.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-05-01
Primary completion date: 2022-02-07
Completion date: 2022-08-01
Plan to share individual participant data: NO
Clinical trial NCT04892043: Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Official title: A Phase 1, Multicenter, Open-Label Study of SQZ-AAC-HPV as Monotherapy and in Combination With Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Sponsor: SQZ Biotechnologies (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Corporate Decision
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-19
Primary completion date: 2023-11-02
Completion date: 2023-11-02
Clinical trial NCT01402284: Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
Official title: Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 45.0 (ACTUAL)
Number of arms: 1.0
Start date: 2011-07-21
Primary completion date: 2016-07-10
Completion date: 2020-09-24
Plan to share individual participant data: NO
Clinical trial NCT02538666: An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy
Official title: A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 451)
Acronym: CheckMate 451
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 907.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-10-13
Primary completion date: 2018-10-01
Completion date: 2021-11-11
Baseline population: All Randomized Participants
Clinical trial NCT04336982: A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
Official title: An Exploratory Phase 1b Open-label Multi-arm Trial to Evaluate the Safety and Efficacy of CC-90009 in Combination With Anti-Leukemia Agents in Subjects With Acute Myeloid Leukemia
Sponsor: Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business objectives have changed.
Enrollment: 22.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-05
Primary completion date: 2023-10-25
Completion date: 2024-04-05
Plan to share individual participant data: YES
IPD sharing description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
IPD time frame: See Plan Description
IPD access criteria: See Plan Description
Clinical trial NCT03844633: Postpartum Family Planning
Official title: Initiation of Injectable Contraception Immediately Postpartum Among Breastfeeding Women
Sponsor: Ohio State University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Because of insufficient enrollment, we closed the RCT and replaced it with an observational design
Enrollment: 49.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-03-21
Primary completion date: 2021-05-26
Completion date: 2022-04-18
Plan to share individual participant data: YES
IPD sharing description: We will welcome collaboration with others who could make use of the study materials and study datasets resulting from the project. Once the primary results are accepted for publication in a peer-reviewed journal, we will make full, de-identified datasets available to individual investigators formally requesting this access.
IPD time frame: Once the primary results are accepted for publication in a peer-reviewed journal, we will make full, de-identified datasets available to individual investigators formally requesting this access.
IPD access criteria: The request should specify the data variables needed, the plan for their analysis, the individuals who will have access to the data, and the plan for destroying the data once the planned analysis is completed. To protect the integrity of the data, the requestor must submit proof of IRB approval or exemption from their institution before we will release the data. The shared data will not contain any individual participant identifiers. The data will be sent in a secured encrypted data file, and the requestors will be responsible for notifying the project PIs upon completion of analysis and specifying the manner in which the data were destroyed. Any presentations, abstracts, or publications will be required to include an acknowledgement of the trial funding source.
Clinical trial NCT02689336: Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
Official title: Phase 2 Clinical Trial Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With the Genomically-Targeted Agent Erlotinib in Combination With Temozolomide
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Could not recruit any participants
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-08-06
Primary completion date: 2019-11-30
Completion date: 2020-05-31
Plan to share individual participant data: NO
Clinical trial NCT03179995: Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy
Official title: GI-072: Randomized Controlled Trial of the Use of Octreotide to Enhance Liver Recovery After Major Hepatectomy
Sponsor: Fox Chase Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Grantor closed study
Enrollment: 23.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-07-07
Primary completion date: 2020-02-12
Completion date: 2020-02-12
Plan to share individual participant data: NO
Clinical trial NCT03889158: Effect of Age and Fitness on Vascular Function and Oxidative Stress During Acute Inflammation
Official title: Effect of Age and Fitness on Vascular Function and Oxidative Stress During Acute Inflammation
Sponsor: University of Illinois at Chicago (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: COVID-19
Enrollment: 35.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-25
Primary completion date: 2020-03-13
Completion date: 2020-03-13
Baseline population: Analysis only completed on individuals with complete data.
Plan to share individual participant data: NO
Clinical trial NCT04052269: Phosphodiesterase Inhibitors in Glaucoma Study (PhiGS)
Official title: A Pilot Study to Investigate the Effect of Phosphodiesterase Inhibitors on Chorioretinal Blood Flow Using Optical Coherence Tomography Angiography.
Acronym: PhiGS
Sponsor: Imperial College London (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: SUSPENDED 
Why stopped: suspended due to COVID
Enrollment: 30.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2019-06-21
Primary completion date: 2021-10-30
Completion date: 2022-10-30
Plan to share individual participant data: NO
Clinical trial NCT03014219: Phase 1 Crohn's Pediatric Sub-study of MSC AFP
Official title: A Phase I Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Fistulizing Crohn's Disease: Pediatric Sub-study
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: FDA approval was not obtained until adult trial completes accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-07-31
Primary completion date: 2019-07-31
Completion date: 2020-07-31
Clinical trial NCT03068247: Neurobiology of Treatment Responses in MDD
Official title: Neurobiology of Non-Specific and Specific Treatment Responses in Major Depression
Sponsor: University of Utah (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Institution was unable to manufacture radiotracer that was central to the protocol. Study transferred to another institution.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-30
Primary completion date: 2023-05-31
Completion date: 2023-05-31
Plan to share individual participant data: NO
Clinical trial NCT03567291: Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
Official title: An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
Acronym: ARTISTS
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The parent trials did not meet the primary endpoints of reduction in motor and phonic tics.
Enrollment: 228.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-05-25
Primary completion date: 2020-05-15
Completion date: 2020-05-15
Baseline population: Intent-to-treat (ITT) analysis set included all enrolled participants.
Plan to share individual participant data: NO
Clinical trial NCT03011307: Efficacy of Intrathecal Oxytocin to Speed Recovery After Hip Surgery
Official title: Efficacy of Intrathecal Oxytocin to Speed Recovery After Hip Surgery
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Cessation of funding period prior to completion, due to slow recruitment during the pandemic.
Enrollment: 126.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-01-12
Primary completion date: 2020-10-23
Completion date: 2021-08-11
Limitations and caveats: The trial was terminated early because of depletion of funding. Power analysis was based on 120 subjects and only 90 were studied before termination of funding .
Plan to share individual participant data: NO
Clinical trial NCT05256277: NK Cell Therapy for AML
Official title: A Phase 1 Study of Evaluating Preliminary Safety and Efficacy of CT101a in the Treatment of Relapsed or Refractory (r/r) AML Patients
Sponsor: Zhejiang University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: A new study is planed to replace the current study due to IP upgrade
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-12-28
Primary completion date: 2022-08-28
Completion date: 2023-04-03
Clinical trial NCT04030052: Emicizumab PUPs and Nuwiq ITI Study
Official title: Emicizumab PUPs and Nuwiq ITI Study
Sponsor: Emory University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: The Emi PUPs and Nuwiq ITI study has been closed due to slow enrollment and study site startup.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-02-17
Primary completion date: 2023-01-19
Completion date: 2023-01-19
Plan to share individual participant data: YES
IPD sharing description: All of the individual participant data that underlie the results reported in the article, after deidentification (text, tables, figures and appendices) will be shared.
IPD time frame: Data will become available beginning 9 months and ending 36 months after publication
IPD access criteria: Data will be shared with investigators/researchers involved in the study approved by the steering committee following verification of sound science for the purpose of achieving aims of the study, meta-analysis and for sound scientific evaluation deemed by the steering committee. Proposal may be submitted up to 36 months following publication and can be accessed following steering committee approval directed to Traci Leong (tleong@emory.edu), the statistician.
Clinical trial NCT04005209: Ketamine Infusion for Sickle Cell Pain Crisis
Official title: Early Low-dose Ketamine Infusion Versus Usual Care for Sickle Cell Pain Crisis: a Randomized, Prospective Study.
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Decided not to open study
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-31
Primary completion date: 2022-11-30
Completion date: 2022-11-30
Plan to share individual participant data: NO
Clinical trial NCT04527354: Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia
Official title: Multicenter, Randomized, Double-blind, Placebo-controlled Pilot Study of Treamid Efficacy and Safety in the Rehabilitation of Patients After COVID-19 Pneumonia
Sponsor: PHARMENTERPRISES LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-01
Primary completion date: 2021-02-10
Completion date: 2021-02-10